DelveInsight’s “Autosomal Dominant Optic Atrophy (ADOA) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Autosomal Dominant Optic Atrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Autosomal Dominant Optic Atrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Autosomal Dominant Optic Atrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Autosomal Dominant Optic Atrophy (ADOA): An Overview
Autosomal dominant optic atrophy (DOA) is a disorder that results from the degeneration of the optic nerve fibers. It is one of the most prevalent forms of inherited optic neuropathies, which are genetic conditions affecting the retinal ganglion cells whose axons constitute the optic nerve. DOA is an important cause of inherited visual failure and occurs equally among males and females. Its prevalence is estimated to be 1 per 30,000 worldwide.
The typical onset of visual loss is in the first or second decade of life, although most patients cannot identify a precise onset of reduced acuity due to the gradual progression. Visual acuity loss is commonly bilateral and relatively symmetric with a mild, slow, and insidious course.
DOA typically affects children before the age of 10, who are often unaware of the problem. Patients typically present with slowly progressive bilateral and symmetrical visual loss, frequently accompanied by centrocecal scotomas. Dyschromatopsia almost always occurs, with blue–yellow and red–green disturbances being the most common. Visual acuity usually ranges between 20/40 and 20/200 but the clinical expression may vary depending on the extent of optic atrophy.
Autosomal Dominant Optic Atrophy (ADOA) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Autosomal Dominant Optic Atrophy pipeline therapies. It also thoroughly assesses the Autosomal Dominant Optic Atrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Autosomal Dominant Optic Atrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Autosomal Dominant Optic Atrophy (ADOA) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Autosomal Dominant Optic Atrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Autosomal Dominant Optic Atrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
Autosomal Dominant Optic Atrophy (ADOA) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Autosomal Dominant Optic Atrophy market or expected to be launched during the study period. The analysis covers the Autosomal Dominant Optic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Autosomal Dominant Optic Atrophy drugs based on their sale and market share.
The report also covers the Autosomal Dominant Optic Atrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Autosomal Dominant Optic Atrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Autosomal Dominant Optic Atrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/autosomal-dominant-optic-atrophy-market
Autosomal Dominant Optic Atrophy (ADOA) Therapeutics Analysis
There is currently no cure for Autosomal Dominant Optic Atrophy (ADOA). Coenzyme Q-10 (CoQ), Idebenone, and nutritional supplements, such as vitamin B12 and C and lutein, have been suggested to reduce reactive oxygen species-induced stress in the optic nerve. Topical agents deemed to be neuroprotective or antiapoptotic, such as brimonidine, have also been recommended although, evidence of their efficacy remains anecdotal. Management generally consists of regular eye exams, including measurement of visual acuity, color vision, visual fields, and optical coherence tomography (OCT). Low-vision aids in individuals with severely decreased visual acuity can be helpful. Gene therapy and RNA interference-based research therapies are under research and development for the treatment of ADOA.
Autosomal Dominant Optic Atrophy (ADOA) Companies Actively Working in the Therapeutics Market Include
-
Stoke Therapeutics
-
PYC Therapeutics
-
Neurophth Therapeutics
And Many Others
Emerging and Marketed Autosomal Dominant Optic Atrophy (ADOA) Therapies Covered in the Report Include:
-
TANGO ASO: Stoke Therapeutics
-
VP-002: PYC Therapeutics
-
NFS-05: Neurophth Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/autosomal-dominant-optic-atrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Autosomal Dominant Optic Atrophy Competitive Intelligence Analysis
4. Autosomal Dominant Optic Atrophy Market Overview at a Glance
5. Autosomal Dominant Optic Atrophy Disease Background and Overview
6. Autosomal Dominant Optic Atrophy Patient Journey
7. Autosomal Dominant Optic Atrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Autosomal Dominant Optic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Autosomal Dominant Optic Atrophy Unmet Needs
10. Key Endpoints of Autosomal Dominant Optic Atrophy Treatment
11. Autosomal Dominant Optic Atrophy Marketed Therapies
12. Autosomal Dominant Optic Atrophy Emerging Drugs and Latest Therapeutic Advances
13. Autosomal Dominant Optic Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Autosomal Dominant Optic Atrophy Market Outlook (In US, EU5, and Japan)
16. Autosomal Dominant Optic Atrophy Companies Active in the Market
17. Autosomal Dominant Optic Atrophy Access and Reimbursement Overview
18. KOL Views on the Autosomal Dominant Optic Atrophy Market
19. Autosomal Dominant Optic Atrophy Market Drivers
20. Autosomal Dominant Optic Atrophy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/autosomal-dominant-optic-atrophy-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Elevate your market presence and strategy in the medical devices’ industry through our meticulous market research services, driving growth and precision in every decision @ Medical Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research